Abstract: A composition for forming a coating film containing fine fibers, imparting an excellent durability to an obtained coating film. The composition for forming a coating film includes the following components (a) and (b): (a) one or more oil agents selected from the group consisting of ester oil, ether oil, hydrocarbon oil and higher alcohol; and (b) a fiber, at 0.5 mass % or more and 10 mass % or less based on the total composition for forming a coating film, the fiber having an average fiber diameter of 0.1 ?m or more and 7 ?m or less. The relationship [(average fiber diameter)2/(fiber content)](?m2/mass %) in the composition is 0.005 or more and 7 or less, and the mass ratio of the component (b) to the component (a), (b/a), is 0.005 or more and 5 or less.

Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.

Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.

Abstract: A polymeric material fiber includes a polymeric material which is a homopolymer of caprolactone or a copolymer of at least 90% by weight of caprolactone and one or more additional monomers. An implantable mesh includes this fiber alone or combined with one or more additional fiber materials. Methods for treating patients involve implanting the fiber material, for example incorporated in a mesh.

Abstract: A compartmented hard shell capsule for containing active formulations, and methods and apparatuses for forming, filling and encapsulating the compartmented hard shell capsules. The compartmented hard shell capsule includes a cap portion and a body portion. The cap portion has a hollow cavity defining a cap chamber. The body portion can be removably inserted into the cap portion. The body portion has an open end, a closed end and a sidewall defining a hollow cavity and a serrated edge along the open end. The serrated edge may be folded over to form a barrier to enclose the body portion, thereby creating a body chamber that is separate from the cap chamber when the body portion is inserted into the cap portion. The methods for filling and encapsulating the compartmented hard shell capsules can be completed in one continuous process, which increases cost-effectiveness for use of the compartmented hard shell capsules.

Abstract: Medical articles formed from a polyurethane-based resin including a modifying oligomer provide enhanced properties. A modifying oligomer incorporated into a backbone, as a side chain, or both of the polyurethane-based resin formed by a diisocyanate, a polyglycol, and a diol chain extender has at least one, preferably two, alcohol moieties (C—OH) and a functional moiety. Exemplary modifying oligomers are: a diol-containing perfluoropolyether incorporated into the backbone, a monofunctional polysiloxane (e.g., monodialcohol-terminated polydimethylsiloxane) incorporated as the side chain, and combinations thereof. Medical articles herein are self-lubricating and/or anti-fouling.

Abstract: Colloidal silver particles are incorporated into emulsions and other compositions that find use, for example, as pharmaceutical and dermatological serums, creams, lotions and ointments.

Abstract: A hair care composition is disclosed comprising an anti-dandruff agent selected from piroctone olamine, selenium sulfide and mixtures thereof and a copolymer comprising acrylamidopropyltrimonium chloride, wherein the weight ratio of the amount of the copolymer to the amount of the anti-dandruff agent is in the range of from 1:5 to 1:1.

Abstract: This invention provides a preparation, composition, product, and application of a photo-coupled synergistically crosslinked hydrogel material. The preparation includes dissolving Component A including a photosensitive polymer derivative having o-nitrobenzyl phototriggers and Component B including a polymer derivative having amine or alkene (double group) or sulfhydryl group in a biocompatible medium to obtain solution A and solution B, respectively; mixing the solution A and solution B homogeneously to obtain a hydrogel precursor solution; initiating photo-coupled synergistic crosslinking under an irradiation of a UV light to form the hydrogel. The irradiation causes the o-nitrobenzyl phototriggers to generate an aldehyde group/keto group or a nitroso group to initiate photo-coupled synergetic crosslinking. The photo-coupled synergistically crosslinked hydrogel has applications in tissue engineering, regenerative medicine, 3D printing and as a carrier of cell, protein or drug.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: Cosmetic compositions capable of forming a multilayer structure after application to a keratinous material are provided, as well as methods of applying such compositions to a keratinous material.

Abstract: Non-degradable, non-immunogenic microporous hydrogel compositions are provided. Such hydrogel compositions consist of flowable hydrogel particles comprising a bioinert polymeric backbone, including for example a poly(ethylene glycol)(PEG)-based polymeric backbone, an annealing component comprising a physiologically-stable, radically polymerizable alkene, including for example methacrylamide, and a heparin compound. Methods of treating glottic incompetence and/or providing laryngeal reconstruction are also provided. Such methods consist of providing a subject suffering from glottic incompetence and/or in need of laryngeal reconstruction, and administering a non-degradable, non-immunogenic microporous hydrogel composition disclosed herein.

Abstract: Disclosed is a novel compound and a process of preparing it. It has been shown to have anti-inflammatory activity and can be utilised in a wide range of cosmetic compositions. The compound is a 2(1H)-pyridinone of formula (1) in amide or enol form. It may be prepared by exposing a solution of piroctone olamine in an organic solvent or in water comprising at least one surfactant to UV radiation to degrade the piroctone olamine. The compound of formula (1) is separated from the degradation products by chromatography.

Abstract: The present disclosure provides a hydrogel tablet for relieving alcoholism and protecting the liver as well as the preparation process and application thereof. The present disclosure firstly provides a composition with the effects of relieving alcoholism and protecting the liver, which comprises the following components on the basis of weight parts: 20˜40 parts of chitosan, 25˜55 parts of sodium alginate, 3˜20 parts of gelatin, 1˜10 parts of calcium carbonate and 0.05˜0.5 parts of gallic acid. Based on this composition, the present disclosure further provides a hydrogel tablet for relieving alcoholism and protecting the liver. In the present disclosure, chitosan, sodium alginate and calcium carbonate are compounded at an appropriate proportion to form powder particles of chitosan/sodium alginate (shell)-calcium carbonate (core), into which are additionally added gelatin and gallic acid to get a product that is the hydrogel tablet.

Abstract: Described herein are compositions composed of a radiopaque agent and a cyanoacrylate monomer. These compositions cure in situ when administered to a subject and, thus, have numerous biomedical applications. The presence of the radiopaque agent allows the practitioner to visualize the compositions during and immediately after administration to the subject. The compositions are non-toxic and shelf-stable, and can be sterilized to prevent microbial growth. The compositions can be pre-mixed prior to sale and distribution, reducing the need for special training in their use.

Abstract: The present invention relates to a topical composition that can be used to treat skin laxity, cellulite and to firm, smooth and/or tone skin.

Abstract: Products configured for oral use and methods for preparing such products are provided. In some embodiments, oral products described herein may comprise at least one active ingredient in an amount of 10 weight percent or less, a sugar alcohol, and a gum, such that the product is in the form of a pastille. In some embodiments, oral products described herein may include at least one active ingredient in an amount of about 10 weight percent or less, a sugar substitute, and a sugar alcohol syrup, such that the product is in the form of a lozenge.

Abstract: A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant. The nanocarrier comprises a porous silicate matrix and particles of a magnetic ferrite disposed in the pores of the porous silicate matrix. The pharmaceutical agent mixture is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK or other kinase inhibitor.

Abstract: The present invention relates to a transdermal therapeutic system for the transdermal administration of guanfacine comprising a guanfacine-containing layer structure, said guanfacine-containing layer structure comprising: A) a backing layer; and B) a guanfacine-containing layer; wherein the transdermal therapeutic system comprises at least one silicone polymer.